JLE

Hématologie

MENU

Détermination de la maladie résiduelle par cytométrie en flux dans la leucémie lymphoïde chronique : état des lieux des pratiques techniques et perspectives Volume 25, supplément 2, Juin 2019

  • [1] Hallek M., Cheson B.D., Catovsky D. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International workshop on chronic lymphocytic leukemia updating the National cancer institute-working group 1996 guidelines. Blood. 2008;111:5446-5456. 10.1182/blood-2007-06-093906 12Erratum in: 2008 ; 112(13) : 5259Blood
  • [2] Hallek M., Cheson B.D., Catovsky D. iwCLL guidelines for diagnosis, indications for treatment, response assessment and supportive management of CLL. Blood. 2018;131:2745-2760. 10.1182/blood-2017-09-806398 25
  • [3] Letestu R., Cartron G., Lepretre S. Minimal residual disease (MRD) by 8-color flow cytometry (Flow-MRD) and IGH clonospecific quantitative PCR (ASO RQPCR) reached similar performances for evaluation of CLL treatment in a phase II clinical trial: cross validation of the methods. Blood. 2014;124:3307. 21
  • [4] Michallet A.-S., Dilhuydy M.-S., Subtil F. High rate of complete response (CR) with undetectable bone marrow minimal residual disease (MRD) after chemo-sparing and MRD-driven strategy for untreated fit CLL patients: final results of the Icll 07 FILO trial. Blood. 2018;132:1858.
  • [5] Böttcher S., Stilgenbauer S., Busch R. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia. 2009;23:2007-2017. 10.1038/leu.2009.140 11
  • [6] Rawstron A.C., Fazi C., Agathangelidis A. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European research initiative on CLL study. Leukemia. 2016;30:929-936. 4
  • [7] Lepretre S., Aurran T., Mahé B. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 2012;119:5104-5110. 22
  • [8] Cartron G., Letestu R., Dartigeas C. Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A french innovative leukemia organization (FILO) study. Haematologica. 2018;103:e356-e359. 10.3324/haematol.2017.182352 8
  • [9] Michallet A.-S., Dilhuydy M.-S., Subtil F. Phase II, multicenter trial, exploring “chemo-sparing” strategy associating obinutuzumab+ibrutinib followed by a MRD driven strategy, in previously untreated symptomatic medically fit chronic lymphocytic leukemia patients (CLL): preliminary results of the induction phase of the Icll-07 FILO study. Blood. 2017;130:497.
  • [10] de Guibert S., Dilhuydy M.-S., Ysebaert L. Bendamustine, ofatumumab and high-dose methylprednisolone (BOMP) in relapsed/refractory CLL: results of a planned interim analysis of the french CLL intergroup ICLL01 phase II trial. Blood. 2014;124:3341.
  • [11] Tournilhac O., Le Garff-Tavernier M., Tabrizi R. RIC allogeneic stem cell transplantation for high risk CLL followed by preemptive MRD-based immunointervention – final results from the phase II ICLL03 Ricac-Pmm trial (FILO – SFGM-TC french intergroup). Blood. 2017;130:4599.
  • [12] Feugier P., Aurran T., Mahé B. Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia. Haematologica. 2018;103:e304-e306. 10.3324/haematol.2017.183350 7
  • [13] Dartigeas C., Van Den Neste E., Léger J. Rituximab maintenance observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematol. 2018;5:e82-e94. 10.1016/S2352-3026(17)30235-1 versus2
  • [14] Rawstron A.C., Böttcher S., Letestu R. Improving efficiency and sensitivity: European research initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia. 2013;27:142-149. 1
  • [15] Debliquis A., Wagner-Ballon O., Le Garff-Tavernier M. Evaluation of paroxysmal nocturnal hemoglobinuria screening by flow cytometry through multicentric interlaboratory comparison in four countries. Am J Clin Pathol. 2015;144:858-868. 10.1309/AJCPWMWJ7XDNQ3SN 6
  • [16] Cazin B., Divine M., Leprêtre S. High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia. Br J Haematol. 2008;143:54-59. 10.1111/j.1365-2141.2008.07309.x 1
  • [17] Sutton L., Chevret S., Tournilhac O. Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. Blood. 2011;117:6109-6119. 10.1182/blood-2010-11-31707
  • [18] Rawstron A.C., Villamor N., Ritgen M. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007;21:956-964. 5
  • [19] Maloum K., Charlotte F., Divine M., Cazin B., Lesty C., Merle-Beral H. A comparison of the sensitivity of flow cytometry and bone marrow biopsy in the detection of minimal residual disease in chronic lymphocytic leukemia. Haematologica. 2006;91:860-861.